Skip to main content
main-content

Type 2 diabetes


Browse the latest news, expert commentary, and educational content on type 2 diabetes.


Highlights

02-22-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

02-05-2021 | Epidemiology | News

Cancer overhauls vascular disease as top cause of death for people with diabetes

The decline in mortality from vascular disease means that cancer is now the leading cause of death in people with diabetes, show data from the UK.

02-03-2021 | Older adults | News

Overtreatment linked to poor outcomes for older adults with diabetes

Researchers find that older adults with diabetes are frequently treated to an intensive glycemic target, putting them at risk for poor outcomes, particularly when high-risk agents are used.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

More on type 2 diabetes

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits